Nurmi, Elias
Vähätalo, Iida
Ilmarinen, Pinja
Andersén, Heidi
Tuomisto, Leena E.
Sovijärvi, Anssi
Backman, Helena
Lehtimäki, Lauri
Hedman, Linnea
Langhammer, Arnulf
Nwaru, Bright I.
Piirilä, Päivi
Kankaanranta, Hannu
Funding for this research was provided by:
Tampere University
Article History
Received: 20 September 2023
Accepted: 4 March 2024
First Online: 15 March 2024
Declarations
:
: Ethics committee of Helsinki University Hospital has approved this study with approval number of 200/13/03/00/15. All patients included in the study have given written informed consent to data usage.
: Not applicable.
: P.I. reports a relationship with GlaxoSmithKline that includes: employment. L.T. reports a relationship with GlaxoSmithKline and AstraZeneca that includes: speaking and lecture fees. H.B. reports a relationship with AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline that includes: speaking and lecture fees. L.L. reports a relationship with ALK, AstraZeneca, Boehringer Ingelheim, Chiesi Pharma, GlaxoSmithKline, MSD, Novartis, Orion Pharma and Sanofi Genzyme that includes: consulting or advisory and speaking and lecture fees. A.L. reports a relationship with AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and with Diagnostica Ltb. that includes: consulting or advisory and speaking and lecture fees. B.N. reports a relationship with DBV Technologies and AstraZeneca that includes: consulting or advisory. H.K. reports a relationship with AstraZeneca, Boehringer Ingelheim, Chiesi Pharma, GlaxoSmithKline, MSD, Novartis, Orion Pharma and Sanofi Genzyme that includes: consulting or advisory and speaking and lecture fees. Other authors report no competing interests.